Printer Friendly

ROBERTS ANNOUNCES CLINICAL TRIAL RESULTS FOR AGRELIN IN THROMBOCYTOSIS

ROBERTS ANNOUNCES CLINICAL TRIAL RESULTS FOR AGRELIN IN THROMBOCYTOSIS
 EATONTOWN, N.J., Jan. 13 /PRNewswire/ -- Roberts Pharmaceutical Corporation (NASDAQ: RPCX) today announced the presentation of two studies describing the therapeutic potential of Agrelin(R) (anagrelide) at the recently held annual meeting of the American Society of Hematology in Denver. Agrelin is a quinazolin derivative which is being developed for the treatment of primary and secondary thrombocytosis associated with certain leukemias and other cancers of the blood forming organs.
 The Mayo Clinic in Rochester, Minn., reported on a collaborative clinical trial of Agrelin involving several centers. Their report concluded that experience with 577 patients indicates that Agrelin safely and effectively reduces dangerously elevated platelet counts (thrombocytosis) associated with bone marrow cancers. M.N. Silverstein, professor of medicine at the Mayo Clinic, reported reductions in platelet counts in 396 of the 424 patients who could be evaluated, a 93 percent response rate. In over four years, only 16 percent of the patients had to discontinue therapy because of side effects. Patients in this study suffer from a variety of blood diseases which can lead to stroke and other life-threatening consequences. Silverstein and his associates will publish their report in the American Journal of Medicine.
 A report from the New York Hospital-Cornell Medical Center Department of Hematology/Oncology, New York, presented results of a collaborative study of 77 patients who had elevated platelet counts associated with chronic myeloid leukemia, all but five of whom had previously received hydroxyurea, a standard but highly toxic therapy for the condition. Ted P. Szatrowski presented the findings of the New York Hospital-Cornell Medical Center study and reported that 52 of 77 patients (68 percent) responded to Agrelin. Of the 19 patients who had been not able to tolerate hydroxyurea, 13 responded. Other patients who probably had been unresponsive to hydroxyurea had a comparable response rate. Szatrowski and his associates, Richard T. Silver, Nehemiah C. Cherig, Timothy S. Gee, Audrey Gutfriend, and Lee P. Schacter concluded that anagrelide is effective in reducing platelet counts and is not associated with unacceptable toxicity.
 Robert A. Vukovich, chairman and CEO of Roberts Pharmaceutical Corporation, stated, "Both studies found Agrelin to effectively reduce the elevated platelet counts in thrombocytosis, a frequent consequence of bone marrow cancers such as leukemia. Left untreated, highly elevated platelet counts are associated with heart attack, stroke and other clotting disorders." Vukovich also indicated that Roberts recently acquired Agrelin from Bristol-Myers Squibb and plans to submit applications throughout the world for marketing the drug.
 Roberts Pharmaceutical Corporation is engaged in the business of acquiring, developing and marketing human pharmaceuticals in the United States and abroad. The company is developing late stage pharmaceuticals for the treatment of cancer, respiratory disease, endocrine disorders, pain management, cardiovascular and urologic conditions. Roberts currently markets a line of prescription and non-prescription pharmaceuticals in the United States and abroad.
 -0- 1/13/92
 /CONTACT: Anthony P. Maris of Roberts Pharmaceuticals, 908-389-1182/
 (RPCX) CO: Roberts Pharmaceutical Corporation ST: New Jersey, Colorado, Minnesota IN: MTC SU:


GK-OS -- NY027 -- 9030 01/13/92 10:51 EST
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 13, 1992
Words:509
Previous Article:WOODHEAD INDUSTRIES EXPECTS FIRST QUARTER SALES AND EARNINGS INCREASE
Next Article:UNION PACIFIC ISSUES ANNOUNCEMENT
Topics:


Related Articles
ROBERTS RECEIVES FDA APPROVAL TO COMMENCE CLINICAL TRIALS WITH DRUG FOR PROSTATE CANCER
ROBERTS PHARMACEUTICAL CORPORATION FILES NEW DRUG APPLICATION FOR AGRELIN WITH FDA
ROBERTS PHARMACEUTICAL CORPORATION RECEIVES CANADIAN REGULATORY APPROVAL FOR AGRELIN(R) TREATMENT IND
ROBERTS PHARMACEUTICAL SUBMITS NEW DRUG APPLICATION TO FDA FOR URINARY INCONTINENCE DRUG
ROBERTS PHARMACEUTICAL CORPORATION DRUG TO RECEIVE HIGH-PRIORITY EC REGULATORY REVIEW
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES ITS AGRELIN NEW DRUG APPLICATION HAS BEEN ACCEPTED FOR FILING BY FDA
ROBERTS PHARMACEUTICAL CORPORATION INFORMED THAT ADDITIONAL INFORMATION IS REQUIRED WITH REGARD TO ITS NEW DRUG APPLICATION FOR PROAMATINE
ROBERTS PHARMACEUTICAL CORPORATION AND FDA TO MEET TO DISCUSS ACCELERATED APPROVAL OF PROAMATINE
ROBERTS PHARMACEUTICAL CORPORATION ANNOUNCES FDA TO APPROVE THE COMPANY'S FIRST PIPELINE DRUG, PROAMATINE, UNDER THE ACCELERATED PROCESS
ROBERTS PHARMACEUTICAL CORPORATION RECEIVES APPROVABLE LETTER AND PREPARES FOR U.S. LAUNCH OF PROAMATINE

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters